MOLECULAR AND IMMUNE INTERDICTION OF AIDS

位于美国艾滋病最严重的中心地带， 爱因斯坦医学院的医生和研究人员 （AECOM）是第一个在临床上面对这种疾病的人之一。 研究和基础研究水平。 AECOM的主要力量在于 在其高度互动的研究历史上， 将实验室获得的结果转化为 临床问题。 AECOM的CFAR吸引了调查人员， 国家和国际声誉，包括四名成员， 美国国家科学院 我们的NIAID资助艾滋病研究基地 包括10项赠款，总额为3，391，795美元，用于支持以下方面的研究： 艾滋病毒感染的流行病学、免疫学和治疗。 我们打算 继续支持互动、协作的广泛研究 越来越多的研究者在多个临床和 以预防和治疗为主要重点的科学学科 艾滋病模式。 我们现在已经做好了充分的准备， 通过改善基础设施，包括：（1）新的7000平方英尺 具有集中数据管理和CFAR专用的管理核心 （2）利用最新技术扩大现有核心 （3）新的生物危害核心， 适应更广泛的研究学科：P3病毒学，SCID- hu/PCR和免疫学/疫苗核心。 所有内核都被大量利用， 多名研究人员，并持续研究和刺激新的 （4）前两个CFAR发展基金的接受者 获得艾滋病赠款，并为CFAR带来了新的关键专业知识; (5)AECOM CFAR已获得研究界的认可， 通过社区，创造一个相互信任的气氛， （6）促进临床和基础研究的合作;（6）财政 CFAR的稳定性已通过收费系统得到保证， 通过当地筹款。 由联合国促进的基础广泛的互动， CFAR取得了突破，如果没有 CFAR基础设施。 用合成的方法已经获得了有希望的结果。 艾滋病疫苗，首次引起粘膜和全身 体液和细胞免疫应答。 基础科学和临床核心的基础设施支持， AECOM CFAR将是成功完成预防和 治疗性疫苗开发。

Situated in the midst of the worst epicenter of AIDS in the U.S., physicians and researchers at the Albert Einstein College of Medicine (AECOM) were one of the first to confront this disease at the clinical research and basic research level. The major strength at AECOM rests upon its history of highly interactive research resulting in the translation of findings obtained in the laboratory into resolution of clinical problems. The CFAR at AECOM has attracted investigators with national and international reputations, including four members of the National Academy of Sciences. Our NIAID funded AIDS Research Base consists of 10 grants at a total of $3,391,795, supporting research on the epidemiology, immunology and treatment of HIV infection. We intend to continue to support interactive, collaborative broad-based research by an increasing number of investigators in multiple clinical and scientific disciplines with a major focus on preventive and therapeutic AIDS modalities. We are now well positioned to enhance our effectiveness through an improved infrastructure including: (1) A new 7000 sq ft administrative core with centralized data management and a CFAR dedicated conference room; (2) Expanded existing core with the latest technology that may not otherwise be obtainable; (3) New biohazard cores to accommodate a broader range of research disciplines: P3 virology, SCID- hu/PCR, and Immunology/Vaccine cores. All cores are heavily utilized by multiple investigators and have sustained research and stimulated new ventures; (4) The two previous recipients of CFAR developmental funds obtained AIDS grants and have brought to the CFAR new critical expertise; (5) The AECOM CFAR has gained recognition by the research community and by the community-at-large, creating a climate of mutual trust and collaboration to foster clinical and basic research; (6) The fiscal stability of the CFAR has been secured through the Charge-Back System and through local fundraising. The broad based interactions fostered by the CFAR yielded breakthroughs that would have been unthinkable without the CFAR infrastructure. Promising results have been obtained with synthetic AIDS vaccines which for the first time induced both mucosal and systemic humoral and cellular immune responses in human volunteers. Infrastructure support from the basic science and clinical cores of the AECOM CFAR will be crucial in the successful completion of preventive and therapeutic vaccine development.